Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with resectable (surgically removable) Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) that has not yet been treated
• People whose lung cancer diagnosis has been confirmed through a tissue sample (pathology)
• People whose doctors have determined that a specific type of targeted therapy (directed at a protein called EGFR) is not the right primary treatment for their cancer
• People who are in good enough general health to undergo the trial treatments, including surgery (measured by a standard health scoring system, with a score of 0 or 1, assessed within 10 days before starting the trial)
• People who are able to provide a tissue sample — either from a previous biopsy or a new one — taken from the primary lung tumour or an affected lymph node

Who may not be able to join:

• People whose NSCLC is located in the superior sulcus (top of the lung near the shoulder), or whose tumour type is large-cell neuroendocrine cancer, a mix of small cell and non-small cell elements, or sarcomatoid tumour
• People who have moderate or severe nerve damage causing symptoms such as numbness or weakness in the hands or feet (Grade 2 or higher peripheral neuropathy)
• People who have a history of severe dry eye syndrome, severe eyelid gland disease, severe eyelid inflammation, or severe corneal disease that affects healing
• People who have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) currently requiring medication to suppress the immune system, or who have a history of these conditions or chronic diarrhoea
• People who have serious, uncontrolled heart or blood vessel disease, or serious uncontrolled brain or blood vessel disease
• People who received a live vaccine within 30 days before the first dose of the trial treatment
• People who received radiation therapy within 2 weeks before starting the trial, or who still have side effects from radiation that require steroid medication
• People who have an immune deficiency condition, or who have been taking steroid medication above a certain dose (more than 10 mg of prednisone or equivalent per day) or other immune-suppressing medication within 7 days before the first trial dose
• People who have another cancer that is currently growing or that has required active treatment within the past 5 years
• People who have had a severe allergic reaction (Grade 3 or higher) to pembrolizumab or any of its ingredients
• People who have an active autoimmune disease that has needed systemic (whole-body) treatment within the past 2 years — note that standard hormone replacement therapies (such as thyroid hormone, insulin, or low-dose steroids) are not counted here (confirm with trial site)
• People who have a history of non-infectious lung inflammation (pneumonitis) or interstitial lung disease that required steroid treatment, or who currently have either of these conditions
• People who have an active infection that requires systemic (whole-body) treatment
• People who have active Hepatitis B or detectable Hepatitis C virus in their blood
• People who have a known history of HIV infection
• People who have previously received a transplant of tissue or a solid organ from another person

Important: Always verify eligibility with the trial site directly before applying.